Daratumumab for relapsed AL amyloidosis—When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review

Tamir Shragai, Moshe Gatt, Noa Lavie, Iuliana Vaxman, Tamar Tadmor, Ory Rouvio, Miri Zektser, Nethanel Horowitz, Hila Magen, Mouna Ballan, Celia Suru, Efrat Luttwak, Shai Levi, Tomer Ziv-Baran, Irit Avivi, Yael C. Cohen

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Objectives: Patients with relapsed/refractory AL amyloidosis (RRAL) have poor prognosis, but emerging data shows promising results with the use daratumumab. We evaluated daratumumab treatment in RRAL in real-world setting. Methods: A retrospective multisite study of RRAL patients treated with daratumumab alone and in combinations. Results: Forty-nine patients, diagnosed between 1.1.2008 and 1.2.2018 were included; 27% also had multiple myeloma (MM). Revised Mayo score was ≥ 3 in 67%. Hematologic overall response rate was 81%, 64% achieved very good partial response (VGPR) or better. Concurrent active MM was associated with lower rates of VGPR (OR 0.19, 95% CI 0.04-0.81; P =.03) in a multi-variate analysis. Cardiac and renal responses were 74% and 73%, respectively. Median progression-free survival (PFS) was 28.4 months and median overall survival (OS) was not reached; 2-year PFS and OS were 68.6 ± 7.5% and 90.4 ± 4.6%, respectively. Hematologic response correlated with prolonged PFS and OS. Daratumumab was safe and well tolerated, no patients discontinued therapy due to toxicity. Our data was aligned with outcomes from a systematic literature review, which identified 10 case series (n = 517) and 2 clinical trials (n = 62) meeting prespecified criteria. Conclusions: Our data support favorable safety tolerability and efficacy of daratumumab among non-selective RRAL patients in a real-world setting.

Original languageEnglish
Pages (from-to)184-195
Number of pages12
JournalEuropean Journal of Haematology
Volume106
Issue number2
DOIs
StatePublished - 1 Feb 2021
Externally publishedYes

Keywords

  • cardiac amyloidosis
  • daratumumab
  • light-chain amyloidosis

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Daratumumab for relapsed AL amyloidosis—When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review'. Together they form a unique fingerprint.

Cite this